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Abstract
Background: Peripheral artery disease (PAD) is a major complication of atherosclerosis. PAD can be diagnosed with
low-cost diagnostic techniques and is associated with significant morbidity and mortality. While the major epidemiologic
risk factors for PAD have been established in the western world, data from resource-poor countries are limited. We
performed a cross-sectional study to determine the prevalence and correlates of PAD among patients with diabetes
at Mbarara Referral Hospital in southwestern Uganda.
Methods: We consecutively enrolled diabetes patients aged 50 years or greater presenting to the outpatient clinic. We
collected blood for fasting lipid profile, HIV serology, and glycosylated hemoglobin, measured blood pressure and
ankle brachial index, and administered the Edinburgh Claudication Questionnaire (ECQ). We also surveyed patients for
other PAD risk factors. We used logistic regression to determine correlates of PAD.
Results: We enrolled 229 diabetes patients. The median age of 60 years (IQR 55–66), and 146 (63.7%) were female. Fifty
five patients (24%) had PAD (ABI of≤0.9). Of these, 48 /55 (87.27%) had mild PAD (ABI 0.71-0.9) while 7/55 (12.73%)
had moderate to severe PAD (ABI<0.7). Amongst those with PAD, 24/55 (43.64%) reported claudication by the
ECQ. Correlates of PAD included female sex (AOR 2.25, 95% CI 1.06 - 4.77, p= 0.034), current high blood pressure
(AOR 2.59, 95% CI 1.25-5.33, p=0.01), and being on a sulfonylurea–glibenclamide (AOR 3.47, 95% CI 1.55 - 7.76,
p=0.002).
Conclusion: P A Dw a sc o m m o ni nd i a b e t i cp a t i e n t si ns o u t h w e s t e r nU g a n d a .G i v e ni t sl o wc o s ta n de a s eo f
measurement, ABI deserves further assessment as a screening tool for both PAD and long term cardiovascular
risk amongst diabetics in this region.
Background
Cardiovascular disease is projected to become the lead-
ing cause of death in sub-Saharan Africa within the next
two decades [1]. This epidemiologic shift will have a sig-
nificant impact on health and relative burden of disease in
the region [2]. Epidemiologic data on non-communicable
diseases in this region are lacking and this is in part due to
the non-availability and high cost of diagnostic tools.
Peripheral arterial disease (PAD) is among those non-
communicable diseases that can be diagnosed without
skilled technologists and at low cost by measurement of
the ankle brachial index (ABI). The ABI, therefore, pre-
sents an attractive screening tool for PAD in resource-
poor settings. Studies in resource-rich settings have
shown that ABI is both sensitive and specific as a meas-
ure of lower extremity large vessel atherosclerosis [3-5].
In western countries, PAD patients are at high risk of
myocardial infarction, stroke, amputations, and cardio-
vascular disease related death. Despite this, many pa-
tients with PAD are asymptomatic [6-8]. PAD, therefore,
is an attractive target for screening because its early de-
tection may not only help to delay its progression, but
may also enable improved management of overall car-
diovascular risk [9-14].
While in resource-rich settings, diabetes, smoking, and
old age have been identified as the most important risk
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rarely diagnosed, in both diabetic and non-diabetic pa-
tients. Consequently, neither is the prevalence of PAD,
nor its risk factors well understood in this region. A bet-
ter understanding of PAD in a population with diabetes
may help guide further research and identify potential
intervention targets. For example, detection of PAD in
such a high risk population may allow for the institution
of relatively simple and low cost medical therapies with
the potential to improve overall cardiovascular risk such
as aspirin, 3-hydroxy-3-methyl-glutaryl-CoA reductase
inhibitors (statins like artovastatin), and angiotensin con-
verting enzyme (ACE) inhibitors [18]. We, therefore, per-
formed a cross-sectional study to determine the prevalence
and correlates of PAD among patients with diabetes at
Mbarara Referral Hospital in Southwestern Uganda. We
hypothesized that diabetic patients in sub-Saharan Africa
would have a prevalence of PAD of 28% (with a 10% preci-
sion) based on what has been found in resource-rich set-
tings (95% CI 19-29%) [19].
Methods
Study design and population
We consecutively enrolled all fasting diabetes patients of
black race, aged≥ 50 years [20], who presented to the
diabetes outpatient clinic at Mbarara Regional Referral
Hospital in Southwestern Uganda, between January and
June 2012. To be included, patients had to have fasted
on the morning of their clinic appointment. Routinely at
this clinic, all patients are advised to fast on the morning
of their clinic appointment to allow for the measurement
of their fasting blood glucose. We excluded patients with
lower limb amputations and those with suspicion of deep
vein thrombosis (i.e., unilateral leg swelling, constant calf-
muscle pain, and pain on foot flexion) for whom ABI test-
ing would have been inappropriate. All patients gave
written informed consent to participate and ethics ap-
proval was obtained from Mbarara University of Science
and Technology and University of Virginia Institutional
Review Boards. The study was registered with the Uganda
National Council of Science and Technology.
Data collection
Clinical and demographic variables
We surveyed the patients to collect data on smoking his-
tory, hypertension, hyperlipidemia, stroke/transient is-
chemic attack, coronary artery disease, or chronic kidney
disease. We also obtained data on the duration of diabetes
and current medications. We categorized self-reported
smoking as never, former, or current. A physician verbally
administered the Edinburgh Claudication Questionnaire
(ECQ). The ECQ has been shown in English speaking
populations to be 91.3% sensitive and 99.3% specific for
identifying claudication symptoms [21]. To adapt it to this
population, the ECQ was pre-tested and translated into
the local language (Runyankole). In addition, we ensured
that it was administered by a physician fluent in the local
language. Given that responses were quantitative, back
translation was not done, and the data was entered dir-
ectly into a database. A composite variable derived from
the responses classified claudication as: none, atypical, or
definite claudication. From the ECQ, definite claudication
was defined as presence of calf pain, regardless of whether
there was pain at other sites. Atypical claudication was de-
fined as having pain in the thigh or buttock in the absence
of calf pain. Finally, no claudication was defined as having
pain in the hamstrings, feet, shins, joints, or any calf, thigh
or buttock pain that appears to radiate, or no pain at all in
any part of the leg [21].
Measurement of ABI
For all patients, we measured the brachial blood pressure
(BP) after a 5-minute rest in the supine position, using an
aneroid sphygmomanometer (Welch Allyn® Tycos DS58
Hand Aneroids; Skaneateles Falls, New York, USA), recali-
brated monthly according to the manufacturers’ manual.
Two BP measurements were taken for each arm with a
third reading performed only if the difference between the
two was greater than 10 mmHg for systolic BP, or greater
than 5 mmHg for diastolic BP. The mean of the closest
two readings was then calculated and taken as the pa-
tient’sB P .
We measured ankle pressures using an aneroid sphygmo-
manometer while using a standardized Doppler ultrasonic
device (8 MHz; Edan™ Sonotrax® MS3-14347A; Shekou,
China) to accentuate the sounds over the posterior tibial
and dorsalis pedis arteries. The ankle–brachial index for
each leg was calculated by dividing the higher of two sys-
tolic BP readings at the ankle (i.e., one from the dorsalis
pedis and the other from the posterior tibial artery) by the
higher of the two brachial systolic BP readings from the
ipsilateral arm (i.e., from the brachial artery). For all pa-
tients, measurements on both legs were obtained, and the
lower value was considered as the patient’s ABI [20,22,23].
Laboratory-based measurements
We measured fasting blood glucose level and glycosyl-
ated hemoglobin (HbA1c) levels using a hand-held gluc-
ometer (Abbott Optium Xceed® Diabetes Monitoring
System; Abbott laboratories™, Illinois, USA) and a standard
HbA1c rapid test kit (A1CNow +®; Bayer™ HealthCare,
Sunnyvale, CA, USA) respectively. We also tested patients
for HIV serology using a standard algorithm and standard
rapid testing kits, with a sensitive initial screen (Alere™
HIV-1/2 Determine® dipstick) followed by a more specific
confirmatory test(STAT-PAK® HIV-1/2), with only the in-
conclusive results being subjected to a third rapid test as a
tie breaker (Uni-Gold™ Recombigen® HIV). In addition, we
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high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C) levels, using an
automated clinical chemistry analyzer (Humastar® 180;
Human Diagnostics Worldwide, Wiesbaden, Germany). The
tests were performed at the Mbarara University Clinical
Research Laboratory which participates in external quality
assurance programs by the National Health Laboratory
Service (Johannesburg, South Africa).
Study definitions
We defined diabetes as a fasting glucose level ≥7.0 mmol/L
(127 mg/dL), or taking medication for diabetes, or having
been diagnosed with diabetes by a physician. We defined
poor glycemic control as HbA1c >7.0% (>53 mmol/mol)
[24]. Hypertension was defined as a systolic blood pres-
sure ≥140 mmHg or diastolic blood pressure≥90 mmHg
or having been on hypertensive medications. Obesity
was defined as a BMI≥ 30 kg/m
2, or a waist-to-hip
ratio≥ 0.81 or ≥ 0.96 for females and males respect-
ively [25]. We defined hypercholesterolemia, high LDL-
cholesterol, low HDL-cholesterol, hypertriglyceridemia,
respectively, as serum cholesterol levels greater than
190 mg/L (4.9 mmol/L), LDL-cholesterol greater than
100 mg/dL (2.50 mmol/L), HDL-cholesterol levels less
than 40 mg/L (1.03 mmol/L), and serum triglyceride levels
greater than 200 mg/L (2.26 mmol/L) respectively [26].
We defined mild PAD as an ABI≥0.71 but≤0.90, moder-
ate PAD as an ABI≥0.40 but≤0.70, and severe PAD as an
ABI<0.40 [20]. We considered a patient with PAD as be-
ing on PAD-appropriate medical therapy if they reported
taking either aspirin or clopidigrel. However, for those
with hypertension required an additional drug in form of
a statin, or an ACEI to be considered as being on PAD ap-
propriate therapy.
Statistical methods
We summarized demographic and clinical characteristics,
reporting proportions for categorical and binary variables,
and median and interquartile range for continuous vari-
ables. We further divided the cohort into those with and
without PAD and fit logistic regression models to deter-
mine the correlates PAD. In the multivariable models,
we adjusted for sex, current high blood pressure, and
taking glibenclamide). Statistical significance was set
at p ≤ 0.05. We performed all statistical analyses using
Stata 12 (StataCorp, College Station, Texas, USA).
Results
Of 256 patients who were screened, 27 did not meet in-
clusion criteria and were excluded. Thirteen were aged ≤
49 years, eight had no diabetes, one had an above-knee
amputation, five declined participation, two withdrew
consent, and one did not complete study procedures.
Summary demographic and clinical characteristics for
the remaining 229 patients are shown in Table 1. The co-
hort had a median age of 60 years, had been known to
be diabetic for a median of 1.0 year (IQR 0.3-2.3), and
had a median HbA1c of 8.1% (6.7-10.1). Twenty-nine per-
cent were taking insulin, and 41% were former or current
smokers.
The prevalence of PAD (ABI of≤0.9) was 24% (55/229).
Among the patients with PAD, 48/55 (87%) had mild PAD
(ABI 0.71-0.90) while 7/55 (13%) had moderate to severe
PAD (ABI<0.70). Based on the ECQ, 31/55 (56%) of those
with PAD were asymptomatic, whereas only 11/55 (20%)
showed definite claudication, and 13/55 (24%) had atypical
Table 1 Characteristics of the study population
Characteristic N=229
Age (years), median (IQR) 60 (55–66)
Female sex, n (%) 146 (63.7)
Current smoker, n (%) 12 (5.2)
Former smoker, n (%) 82 (35.8)
Never smoked 135 (59)
Duration of diabetes (years), median (IQR) 1.0 (0.3–2.3)
Family history of diabetes, n (%) 78 (34.1)
No Claudication, n (%) 126 (55.0)
Atypical Claudication, n (%) 54 (23.6)
Definite Claudication, n (%) 49 (21.4)
Self-reported hypertension, n (%) 113 (49.3)
HIV infection, n (%) 18 (7.9)
Diabetes treatment
π, n (%)
Metformin only 112 (51.6)
Glibenclamide only 2 (0.9)
Glibenclamide and Metformin 34 (15.7)
Insulin only 52 (24)
Insulin and Metformin 15 (6.9)
Aspirin, n (%) 17 (7.4)
BMI (kg/m
2), median (IQR) 26.3 (22.6–29.4)
Waist-to-hip ratio, median (IQR) 1 (1–1)
Systolic blood pressure (mmHg), median (IQR) 140 (124–160)
Diastolic blood pressure (mmHg), median (IQR) 80 (70–90)
Fasting blood sugar (mmol/L), median (IQR) 8.6 (6.6–13.7)
HbA1c (%), median (IQR) 8.1 (6.7–10.1)
HDL
£-Cholesterol (mg/dL), median (IQR) 48 (39–58)
LDL
¥-Cholesterol (mg/dL), median (IQR) 81 (63–96)
Triglycerides (mg/dL), median (IQR) 116 (83–179)
Total cholesterol (mg/dL), median (IQR) 268 (212–307)
IQR: Inter quartile range; HIV: Human immunodeficiency virus; BMI: body mass
index; HDL
£: High-density Lipoprotein- cholesterol; LDL
¥: Low-density
lipoprotein-cholesterol; HbA1c: glycated hemoglobin.
Diabetes treatment
π: A total of 217 patients were on diabetes medication.
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PAD, 6/55 (11%) were taking aspirin, and only 1 patient
was taking a statin. Thirty three of 113 (29.2%) patients
who had hypertension with concurrent PAD were on an
ACE inhibitor or ARB.
In the unadjusted analysis (Table 2), female sex, self-
reported hypertension, current high blood pressure, and
duration of diabetes were associated with PAD. In the
multivariable adjusted analysis, (Table 3), female sex
(AOR 2.25, 95% CI 1.06–4.77, p=0.034), current high
blood pressure (AOR 2.59, 95% CI 1.25–5.33, p= 0.01),
and being on sulfonylurea–glibenclamide (AOR 3.47,
95% CI 1.55–7.76, p =0.002) were independently associ-
ated with PAD.
Discussion
To the best of our knowledge, this is the first report of
the prevalence of PAD in patients with diabetes in Sub-
Sahara Africa. The prevalence of PAD of 24%, as found
in our study based on ABI, was substantially higher than
previous estimates (0.2–3.4%) which were based on clin-
ical parameters such as weak or absent peripheral pulses,
or development of dry gangrene [27,28]. However, our
finding is comparable to the upper end of the range
(1.7–28%) found when ABI was measured by echo-
graphic and doppler flow velocity waveform analysis
methods [2]. The prevalence of PAD in our study popula-
tion is also well within the range of several screening stud-
ies in the US that used a similar screening technique, and,
in African American diabetic patients, found a prevalence
of PAD between 14-30% [29-31]. The low proportion of
smokers in our study (5.2%) reflects the low national
smoking prevalence in Uganda [32].
In the multivariable-adjusted analysis, we found that
female sex, current high blood pressure, and use of glib-
enclamide were predictive of PAD. Population based
studies have previously reported an association of PAD
with female sex [33] and hypertension [34], which we
have also shown in our study. In our clinic, the majority
of the patients are of the female sex [35]. This pattern
may be because females generally outnumber males in
the Ugandan population and, in addition, they tend to
have better health seeking behaviour [36,37]. We were
unable to assess independent association of smoking
with PAD because of a very low prevalence of smoking.
A low prevalence of smoking has been reported in the
general Ugandan population, and the prevalence is even
lower in females [32,35,37]. It is therefore possible that
the observed lack of association with smoking with PAD
may be due to the high female proportion in the setting
of a low prevalence of smoking in females. Given this
observation, the finding that female sex was an inde-
pendent predictor of PAD may or may not represent a
real association in this population, and, therefore, de-
serves further investigation in future studies.
Despite international recommendations for use of as-
pirin, ACEIs, and statins for PAD [18], our study shows
that diabetes patients are undertreated with regard to
atherosclerotic risk factor modification. This may be be-
cause patients with diabetes can be asymptomatic even
in the presence of serious cardiovascular complications.
PAD screening in these patients may therefore enhance
the awareness of active cardiovascular complications and
allow for more risk factor treatment. We do appreciate
that there can be a high rate of noncompliance to medi-
cation for chronic non-communicable disease is in our
setting. However, our finding of a high prevalence of
Table 2 Unadjusted analysis of predictors of Peripheral
Artery Disease
Characteristic OR (95% CI) p-value
Female sex 2.47 (1.22–5.01) 0.0001
Smoking history 1.04 (0.56–1.93) 0.894
Duration of diabetes >5 years 3.38 (0.94–12.15) 0.062
Family history of diabetes 1.37 (0.73–2.56) 0.326
Presence of claudication symptoms 0.93 (0.51–1.71) 0.819
Self-reported hypertension
¥ 1.96 (0.95–3.26) 0.072
Current elevated blood pressure
β 2.73 (1.42–5.25) 0.003
HIV infection 0.61 (0.17–2.19) 0.451
Metformin use 0.74 (0.39–1.42) 0.367
Glibenclamide use 3.16 (1.50–6.66) 0.002
Insulin use 1.24 (0.65–2.38) 0.517
Obesity, BMI≥30 Kg/m
2 1.23 (0.59–2.53) 0.576
Waist-to-hip ratio≥0.81 (F) or ≥0.96 (M) 0.83 (0.21–3.26) 0.796
Cholesterol ≥190 mg/dL 0.9 (0.41–1.98) 0.794
HDL
€≤40 mg/dL 1.21 (0.61–2.41) 0.581
LDL
α≥100 mg/dL 1.39 (0.69–2.78) 0.355
TG
∞≥200 mg/dL 0.75 (0.34–1.67) 0.483
FBS
μ <3.9 or >7.2 mmol/L 0.87 (0.46–1.65) 0.679
HbA1c
£ >7.0% (53 mmol/mol) 0.75 (0.39 - 1.41) 0.368
Self-reported hypertension
¥: prior diagnosis of hypertension and taking
antihypertensive drugs; Current elevated blood pressure
β: clinic systolic blood
pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; OR: Odds
ratio; BMI: body mass index; HDL
€: High-density Lipoprotein- cholesterol; LDL
α:
Low-density lipoprotein-cholesterol; TG
∞: Triglycerides; FBS
μ: fasting blood
sugar; HbA1c
£: glycated hemoglobin.
Table 3 Multivariable adjusted predictors of Peripheral
Artery Disease
Characteristic AOR 95% CI p-value
Glibenclamide use 3.47 1.55 - 7.76 0.002
Current high blood pressure
β 2.59 1.25 - 5.33 0.01
Female sex 2.25 1.06 - 4.77 0.034
Current high blood pressure
β: clinic measured systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure ≥90 mmHg; AOR: Adjusted odds ratio.
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existence of prevention opportunities in this population.
Although sulfonylureas, including glyburide and glicla-
zide, have been associated with an increased mortality
from acute coronary syndrome in type 2 diabetes patients
[38], we know of no prior study that has reported an asso-
ciation between glibenclamide use and PAD. This may,
therefore, be a spurious finding from our study. However,
the association was independent of concurrent metformin
use, diabetes duration and severity (as assessed through
HbA1c). In addition, those taking insulin were not at
increased risk of PAD, indicating the increased risk of
PAD in those on glibenclamide may not be related to the
known risk of hypoglycemia that occurs with glibencla-
mide. Thus, our findings may suggest an independent as-
sociation between PAD and glibenclamide use (Table 3)
requiring further investigation.
Previous studies have reported that even among pa-
tients with a low ABI and thus confirmed PAD, absence
of “leg” symptoms is not very useful in excluding PAD
[6,20]. We found that only 20% of those with PAD had
definite claudication, and that over half had no claudica-
tion symptoms on the ECQ. This is similar to what has
been found by studies in resource rich settings where
this tool showed 20% sensitivity in diagnosing PAD [16].
Our data similarly suggest that claudication symptoms
are not very helpful in excluding PAD in Sub-Saharan
Africa.
The findings in this report are subject to a number of
limitations. First, this was a cross sectional study in a
population with diabetes where the risk for PAD is high.
Second, the patients studied were from a referral center.
These observations imply that our findings may not neces-
sarily represent the general Ugandan population, or those
patients presenting in primary care settings. In addition,
our findings may not reflect the prevalence of PAD if it
was measured using other screening criteria. However, our
data suggest that criteria applied in resource-rich settings
may as well be applicable in the resource-poor setting.
Conclusion
In conclusion, PAD was common among diabetes outpa-
tients ≥ 50 years old presenting at a referral hospital in
southwestern Uganda. Given that this is a group at high
risk of cardiovascular complications, the high prevalence
of PAD in a setting of under-treatment of general car-
diovascular risk, call for further study of PAD in this
population. For example, future studies could investigate
whether screening for PAD in this population using
ABIs might lead to increased use of evidence-based
treatments that are known to reduce general cardiovas-
cular risk. Future research should also attempt to deter-
mine the prevalence and risk factors of PAD in more
generalized populations in sub-Saharan Africa.
Abbreviations
ABI: Ankle-Brachial Index, PAD, Peripheral Artery Disease, AOR, Adjusted Odds
Ratio.
Competing interests
The authors prepared this report in their roles as employees of their
respective institutions. They have no financial or other potential conflict of
interest with regard to this manuscript.
Author contributions
SO, AM, RO, SBA, and BHA conceived the study, collected the data,
contributed to discussion, and reviewed, edited, and wrote the manuscript.
MJS, JR, LAW, CCM, and BHA contributed to discussion and reviewed and
edited the manuscript. S.O and C.C.M analyzed the data. SO is the guarantor
of this work and, as such, had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data
analysis. All authors read and approved the final manuscript.
Acknowledgements
We acknowledge that our study was supported in part by funds from the
Ruth and Frank Dunlap Research Endowment at Division of Cardiovascular
Medicine and the Center for Global Health at the University of Virginia. All
authors read and approved the final manuscript.
Author details
1Department of Medicine, Mbarara University of Science and Technology,
P.O Box 1410, Mbarara, Uganda.
2Department of Medicine, University of
Virginia, Charlottesville, Virginia, USA.
3Department of Medicine, Mbarara
Regional Referral Hospital, Mbarara, Uganda.
4Harvard Medical School,
Boston, Massachusetts, United States of America.
5The Robert M. Berne
Cardiovascular Research Center, University of Virginia, Charlottesville,
Virginia, USA.
Received: 5 March 2014 Accepted: 5 June 2014
Published: 10 June 2014
References
1. Mathers CD, Loncar D: Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 2006, 3(11):e442.
2. Kengne AP, Amoah AGB, Mbanya JC: Cardiovascular complications of
diabetes mellitus in sub-Saharan Africa. Circulation 2005, 112(23):3592–3601.
3. Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F: Inter-society
consensus for the management of peripheral arterial disease (TASC II).
J Vasc Surg 2007, 45(1):5.
4. Zheng Z-J, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS,
Dobs A, Evans GW, Heiss G: Associations of ankle-brachial index with
clinical coronary heart disease, stroke and preclinical carotid and
popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC)
Study. Atherosclerosis 1997, 131(1):115–126.
5. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR,
Howard BV: Relationship of high and low ankle brachial index to all-cause
and cardiovascular disease mortality. Circulation 2004, 109(6):733–739.
6. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW,
Krook SH, Hunninghake DB, Comerota AJ, Walsh ME: Peripheral arterial
disease detection, awareness, and treatment in primary care. Jama 2001,
286(11):1317–1324.
7. Elhadd T, Robb R, Jung R, Stonebridge P, Belch J: Pilot study of prevalence
of asymptomatic peripheral arterial occlusive disease in patients with
diabetes attending a hospital clinic. Pract Diab Int 1999, 16(6):163–166.
8. Fowkes F, Murray G, Butcher I, Folsom A, Hirsch A, Couper D, DeBacker G,
Kornitzer M, Newman A, Sutton-Tyrrell K: Development and validation of
an ankle brachial index risk model for the prediction of cardiovascular
events. Eur J Prev Cardiol 2014, 21(3):310–320.
9. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ,
Browner D: Mortality over a period of 10 years in patients with
peripheral arterial disease. N Engl J Med 1992, 326(6):381–386.
1 0 . M u r a b i t oJ M ,E v a n sJ C ,L a r s o nM G ,N i e t oK ,L e v yD ,W i l s o nP W :The
ankle-brachial index in the elderly and risk of stroke, coronary disease, and
death: the Framingham Study. Arch Intern Med 2003, 163(16):1939.
Okello et al. BMC Cardiovascular Disorders 2014, 14:75 Page 5 of 6
http://www.biomedcentral.com/1471-2261/14/7511. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC:
Predictive value of noninvasive measures of atherosclerosis for incident
myocardial infarction. Circulation 2004, 109(9):1089–1094.
12. Collaboration ABI, Fowkes F, Murray G, Butcher I, Heald C, Lee R, Chambless L,
Folsom A, Hirsch A, Dramaix M: Ankle brachial index combined with
Framingham risk score to predict cardiovascular events and mortality.
JAMA 2008, 300(2):197–208.
13. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A,
Bundens WP, Fronek A: Ethnicity and Peripheral Arterial Disease The San
Diego Population Study. Circulation 2005, 112(17):2703–2707.
14. Allison MA, Criqui MH, McClelland RL, Scott JAM, McDermott MM, Liu K,
F o l s o mA R ,B e r t o n iA G ,S h a r r e t tA R ,H o m m aS :The effect of novel
cardiovascular risk factors on the ethnic-specific odds for peripheral
arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA).
J Am Coll Cardiol 2006, 48(6):1190–1197.
15. Association AD: Peripheral arterial disease in people with diabetes.
Clinical Diabetes 2004, 22(4):181–189.
16. PERIPHERAL IO: Peripheral arterial disease in people with diabetes.
Diabetes Care 2003, 26(12):3333.
17. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE:
Peripheral arterial disease in the elderly: the Rotterdam Study.
Arterioscler Thromb Vasc Biol 1998, 18(2):185–192.
18. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian
J, Gornik HL, Halperin JL, Jaff MR: 2011 ACCF/AHA focused update of the
guideline for the management of patients with peripheral artery disease
(updating the 2005 guideline) a report of the American college of
cardiology foundation/American heart association task force on practice
guidelines. J Am Coll Cardiol 2011, 58(19):2020–2045.
19. Blodget E, Shen C, Aldrovandi G, Rollie A, Gupta SK, Stein JH, Dubé MP:
Relationship between Microbial Translocation and Endothelial Function
in HIV Infected Patients. PLoS One 2012, 7(8):e42624.
20. Creager MA, Belkin M, Bluth EI, Casey DE, Chaturvedi S, Dake MD, Fleg JL,
Hirsch AT, Jaff MR, Kern JA: 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/
SVS Key Data Elements and Definitions for Peripheral Atherosclerotic
Vascular Disease: A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Clinical Data
Standards (Writing Committee to Develop Clinical Data Standards for
Peripheral Atherosclerotic Vascular Disease). J Am Coll Cardiol 2012,
59(3):294–357.
21. Lend G, Fowkes F: The Edinburgh Claudication Questionnaire: an
improved version of the WHO/Rose Questionnaire for use in
epidemiological surveys. J Clin Epidemiol 1992, 45(10):1101–1109.
22. Holland-Letz T, Endres HG, Biedermann S, Mahn M, Kunert J, Groh S, Pittrow D,
Von Bilderling P, Sternitzky R, Diehm C: Reproducibility and reliability of the
ankle—brachial index as assessed by vascular experts, family physicians
and nurses. Vasc Med 2007, 12(2):105–112.
23. Heald C, Fowkes F, Murray G, Price J: Risk of mortality and cardiovascular
disease associated with the ankle-brachial index: Systematic review.
Atherosclerosis 2006, 189(1):61–69.
24. Marso SP, Hiatt WR: Peripheral arterial disease in patients with diabetes.
J Am Coll Cardiol 2006, 47(5):921–929.
25. Ashwell M, Gunn P, Gibson S: Waist‐to‐height ratio is a better screening
tool than waist circumference and BMI for adult cardiometabolic risk
factors: systematic review and meta‐analysis. Obes Rev 2012, 13(3):275–286.
26. Lorenzo C, Williams K, Hunt KJ, Haffner SM: The National Cholesterol
Education Program–Adult Treatment Panel III, International Diabetes
Federation, and World Health Organization definitions of the metabolic
syndrome as predictors of incident cardiovascular disease and diabetes.
Diabetes Care 2007, 30(1):8–13.
27. Rolfe M: Macrovascular disease in diabetics in Central Africa. Br Med J
(Clin Res Ed) 1988, 296(6635):1522.
28. Elmahdi E, Kaballo A, Mukhtar E: Features of non-insulin-dependent
diabetes mellitus (NIDDM) in the Sudan. Diabetes Res Clin Pract 1991,
11(1):59–63.
29. Aponte J: The prevalence of peripheral arterial disease (PAD) and PAD
risk factors among different ethnic groups in the US Population.
J Vasc Nurs 2012, 30(2):37–43.
30. Lange S, Diehm C, Darius H, Haberl R, Allenberg JR, Pittrow D, Schuster A,
von Stritzky B, Tepohl G, Trampisch HJ: High prevalence of peripheral
arterial disease but low antiplatelet treatment rates in elderly primary
care patients with diabetes. Diabetes Care 2003, 26(12):3357–3358.
31. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burt V,
Curtin L, Engelgau M, Geiss L: Prevalence of Lower-Extremity Disease in
the US Adult Population≥40 Years of Age With and Without Diabetes
1999–2000 National Health and Nutrition Examination Survey.
Diabetes Care 2004, 27(7):1591–1597.
32. Maher D, Waswa L, Baisley K, Karabarinde A, Unwin N, Grosskurth H:
Distribution of hyperglycaemia and related cardiovascular disease risk
factors in low-income countries: a cross-sectional population-based
survey in rural Uganda. Int J Epidemiol 2011, 40(1):160–171.
33. Aboyans V, Criqui MH, McClelland RL, Allison MA, McGrae McDermott M,
Goff DC, Manolio TA: Intrinsic contribution of gender and ethnicity to
normal ankle-brachial index values: the Multi-Ethnic Study of
Atherosclerosis (MESA). J Vasc Surg 2007, 45(2):319–327.
34. Guerchet M, Aboyans V, M’Belesso P, Mouanga AM, Salazar J, Bandzouzi B,
Tabo A, Lacroix P, Preux P-M: 241 Particularities of the epidemiology
of lower-extremities peripheral artery disease in Central Africa.
Arch Cardiovasc Dis Supplements 2010, 2(1):77.
35. Namusisi O, Sekandi JN, Kasasa S, Wasswa P, Kamara NT, Medard B, Mihayo P,
Gitta SN, Mukanga D: Risk factors for non-communicable diseases in rural
Uganda: a pilot surveillance project among diabetes patients at a referral
hospital clinic. Pan African Medical Journal 2011, 10(1):47.
36. Lawson D: Determinants of Health Seeking Behaviour in Uganda: Is it
Just Income and User Fees that are Important? Manchester, England:
University of Manchester; 2004.
37. Inc UBoSUaII: Uganda Demographic and Health Survey. In ICF International
Inc. Calverton, Maryland: UBOS; 2012.
38. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM,
Masotti G, Marchionni N, Mannucci E: Three year mortality in diabetic
patients treated with different combinations of insulin secretagogues
and metformin. Diabetes Metab Res Rev 2006, 22(6):477–482.
doi:10.1186/1471-2261-14-75
Cite this article as: Okello et al.: Prevalence of lower extremity
Peripheral artery disease among adult diabetes patients in
Southwestern Uganda. BMC Cardiovascular Disorders 2014 14:75.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Okello et al. BMC Cardiovascular Disorders 2014, 14:75 Page 6 of 6
http://www.biomedcentral.com/1471-2261/14/75